文献速递血栓与止血

血栓预防对COVID-19住院患者出院后医院获得性血栓的影响:英国多中心观察性研究

Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: Multicentre observational study in the UK.
PubMed 文献 · Br J Haematol · 2023-05-18

该多中心观察性研究纳入英国26个NHS信托机构2020年4月1日至2021年12月31日期间因COVID-19住院后出院的8895例成人患者,将971例出院时接受血栓预防的患者与未接受者按1:1倾向性评分匹配。出院后血栓预防中位持续4周(1-8周),接受与未接受血栓预防的患者医院获得性血栓发生率无差异(1.3% vs 0.92%,p=0.52);年龄增长和吸烟显著增加医院获得性血栓风险。

要点

  • 出院后接受血栓预防与未接受者医院获得性血栓发生率无差异(1.3% vs 0.92%,p=0.52)。
  • 出院后血栓预防中位持续时间为4周(范围1-8周)。
  • 年龄增长和吸烟显著增加医院获得性血栓风险。

核心结论

  • 出院后血栓预防与未接受者相比医院获得性血栓发生率无差异(1.3% vs 0.92%,p=0.52)。
  • 年龄增长和吸烟显著增加医院获得性血栓风险。
  • 两组出院时许多患者D-二聚体升高,但D-二聚体与医院获得性血栓风险增加无关。

研究设计与样本

  • 多中心观察性研究,覆盖英国26个NHS信托机构,纳入2020年4月1日至2021年12月31日期间因COVID-19住院后出院的≥18岁患者。
  • 共纳入8895例患者,其中971例出院时接受血栓预防,并与出院时未接受血栓预防的患者按1:1倾向性评分匹配。
  • 排除肝素诱导的血小板减少症、住院期间大出血及妊娠女性。

主要发现

  • 1:1倾向性评分匹配后两组参数(包括住院时长)无差异,但血栓预防组住院期间接受治疗剂量抗凝的比例显著更高。
  • 两组入院时及出院时实验室参数(尤其D-二聚体)无差异。
  • 出院后血栓预防中位持续4周(1-8周)。
  • 接受与未接受血栓预防的患者医院获得性血栓发生率无差异(1.3% vs 0.92%,p=0.52)。
  • 年龄增长和吸烟显著增加医院获得性血栓风险;出院时D-二聚体升高与医院获得性血栓风险增加无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Post-discharge thromboprophylaxis in patients admitted with COVID-19 remains controversial. We aimed to determine the impact of thromboprophylaxis on hospital acquired thrombosis (HAT) in patients (≥18 years) discharged following admission for COVID-19 in an observational study across 26 NHS Trusts in the UK (01.04.2020-31.12.2021). Overall, 8895 patients were included to the study: 971 patients were discharged with thromboprophylaxis and propensity score matched (PSM) with a desired ratio of 1:1, from patients discharged without thromboprophylaxis. Patients with heparin induced thrombocytopenia, major bleeding during admission and pregnant women were excluded. As expected from 1:1 PSM, no difference was observed in parameters between the two groups, including duration of hospital stay, except the thromboprophylaxis group had a significantly higher proportion who had received therapeutic dose anticoagulation during admission. There were no differences in the laboratory parameters especially D-dimers between the two groups at admission or discharge. Median duration of thromboprophylaxis following discharge from hospital was 4 weeks (1-8 weeks). No difference was found in HAT in patients discharged with TP versus no TP (1.3% vs. 0.92%, p = 0.52). Increasing age and smoking significantly increased the risk of HAT. Many patients in both cohorts had raised D-dimer at discharge but D-dimer was not associated with increased risk of HAT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Arachchillage DJ, Rajakaruna I, Odho Z, et al. Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: Multicentre observational study in the UK. Br J Haematol. 2023. PMID: 37202865. doi:10.1111/bjh.18874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。